Ertapenem

Restricted
Restricted

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

$75/day

Dosing

Infants and Children
30 mg/kg/day divided q12h (up to 500 mg/dose)

Adolescents
1000 mg IV q24h

1g IV q24h

General Information

Common Usage

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

Adverse Effects

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Additional Information

Infectious Diseases Consultation required.

Pharmacology

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic